Case reports demonstrate improvement in Crohn's disease and atopic dermatitis symptoms with Upadacitinib treatment.
Upadacitinib (UPA), a selective Janus kinase 1 inhibitor, is approved for treating both Crohn's disease (CD) and atopic dermatitis (AD). However, clinical experience in patients with coexisting CD and AD is limited. We report two adult men with concurrent CD and AD who were treated with UPA. In both cases, the intestinal and cutaneous symptoms improved within one month of treatment, followed by the endoscopic remission of CD and continued control of AD. Disease control was maintained after the dose reduction. These cases suggest that UPA may be a useful therapeutic option for selected patients with coexisting CD and AD.
No takes yet. Share an insight, caveat, or question.
Kojima et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: